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Bayesian analyses of symptomatic intracranial stenosis studies were conducted to compare the benefits of
long-term therapy with warfarin to aspirin. The synthesis of evidence of effect from previous nonrandomized studies in monitoring a randomized clinical trial was of particular interest. Sequential
Bayesian learning analysis was conducted and Bayesian hierarchical random effects models were used to
incorporate variability between studies. The posterior point estimates for the risk rate ratio (RRR) were
similar between analyses, although the interval estimates resulting from the hierarchical analyses are
larger than the corresponding Bayesian learning analyses. This demonstrated the difference between these
methods in accounting for between-study variability. This study suggests that Bayesian synthesis can be a
useful supplement to futility analysis in the process of monitoring randomized clinical trials.
Key words: Bayesian analysis, Bayesian hierarchical model, Bayesian learning, randomized clinical trial,
epidemiology, stroke.
Although Bayesian methods are
growing in acceptance in the RCT community,
their use in stroke RCTs is still debated (Berry
2005, Donnan, Davis & Ludbrook, 2005;
Howard, Coffey & Cutter, 2005; Krams, Lees &
Berry, 2005). This study explores the use of two
Bayesian techniques for synthesis of evidence.
Specifically sequential Bayesian learning and
hierarchical Bayesian models are used (Gelman,
Carlin, Stern & Rubin, 2004) to examine results
from accumulating studies, then illustrate their
application to the Warfarin v Aspirin for
Symptomatic Intracranial Disease (WASID)
trial.

Introduction
A responsibility of the committees charged with
monitoring randomized clinical trials is to track
new evidence from similar studies. However,
there are no specific guidelines for the assembly
and analysis of such information. Recently the
use of Bayesian methods has become accepted
in the randomized clinical trials (RCT)
community. (Berry, Berry, McKellar & Pearson,
2003). One area in which Bayesian methods are
useful is in the synthesis of evidence.
(Spiegelhalter, Abrams & Myles, 2004) Thus
such methods could provide a data safety
committee with useful insights into relevant
external information accumulating during the
course of a study.

WASID Background
A long-standing secondary stroke
prevention
strategy
for
patients
with
symptomatic intracranial atherostenosis has been
warfarin therapy. Warfarin’s use was predicated
on evidence published in a case series from the
Mayo Clinic in the 1950’s (Millikan, Siekert &
Shick, 1954). This finding was subsequently
supported by similarly positive results in
observational studies (Marzewski, et al,. 1982;
Moufarrij, Little, Furlan, Williams &
Marzewski, 1984; Chimowitz, et al., 1995; Thijs
& Albers, 2000; Qureshi, et al., 2003)
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intermittent insufficiency of the basilar system
or thrombosis within the basilar arterial system.
They found that 10/23 (43%) of patients who did
not receive anticoagulant therapy died,
compared to 3/21 (14%) of patients receiving
anticoagulants. The estimated odds ratio (OR)
for death comparing aspirin to warfarin (with
associated 95% confidence interval [CI]) is 4.62
(2.18, 9.79).
Study 2: Chimowitz, et al. (1995)
assessed
cases
with
symptomatic,
angiographically confirmed stenosis (≥ 50%) of
a major intracranial artery in a retrospective,
non-randomized cohort study. Of the 151
patients included in the study, 88 were treated
with warfarin and 63 were treated with aspirin.
Treatments and dosages were chosen by local
physician. Patients were followed by chart
review and telephone or personal / next-of-kin
interview until first occurrence of a primary
endpoint (major vascular event defined as
ischemic stroke, myocardial infarction or sudden
death), change in therapy (from aspirin to
warfarin or vice versa), or last contact or death
due to non-vascular cause. Warfarin patients
were followed for a median duration of 14.7
months, experiencing 8.4 major vascular events
per 100 patient years of follow-up. Aspirin
patients were followed for a median duration of
19.3 months, experiencing 18.1 major vascular
events per 100 patient years. The estimate of
relative risk (RR) of major vascular events in
aspirin patients compared to warfarin patients is
2.2 (95% CI, 1.2, 4.4).
Study 3: Thijs and Albers (2000)
interviewed 51 patients identified from chart
review. All patients had symptomatic
intracranial
stenosis
and
had
failed
antithrombotic therapy. Of these, 32 patients
were followed on warfarin and 19 on aspirin.
Cox proportional hazards analysis was
conducted to estimate the hazard ratio (HR) for
cerebral ischemic events (including TIA) after
adjusting for age, presence of anterior
circulation disease, Caucasian race, and
hyperlipidemia. The estimated aspirin to
warfarin HR is 4.9 (95% CI, 1.7, 13.9).
Study 4: Qureshi, et al. (2003)
retrospectively assessed 102 patients with
symptomatic vertebrobasilar stenosis. Cox
proportional hazards analysis gave an estimated

In 1998, the National Institute of
Neurological Diseases and Stroke (NINDS)
funded the Warfarin vs Aspirin for Symptomatic
Intracranial Disease (WASID) study, the first
double-blinded, placebo-controlled randomized
clinical trial (RCT) to test the superiority of
warfarin (International Normalized Ratio [INR]
2 – 3) over high-dose aspirin (650 mg twice
daily) in this patient population. The protocol
called for enrollment of 806 patients with
angiographically
proven
symptomatic
intracranial disease to determine a combined
endpoint of stroke (ischemic and hemorrhagic)
and vascular death. The sample size was chosen
to give 80% power to detect a difference
between event rates of 33% in the aspirin group
compared to 22% in the warfarin group over 3
years after, accounting for a 24% rate of
discontinuation of study medications and 1%
loss to follow-up, which translates to an
alternative hazard ratio (HR) of 1.47.
In July, 2003, after 569 patients were
enrolled, NINDS, acting upon advice from the
WASID Performance and Safety Monitoring
Board (PSMB), stopped WASID because
subjects randomized to warfarin were at
significant increased risk of major non-endpoint
adverse events and the potential for a benefit in
primary endpoint events that was sufficient to
outweigh these adverse events was very low.
Indeed, after study closeout, there was no
advantage of warfarin versus aspirin (HR = 1.04;
95% CI = 0.73 to 1.48) (Chimowitz, et al.,
2005).
Description of Prior Evidence
Existing literature on warfarin treatment
for intracranial stenosis was reviewed (Millikan,
et al., 1954; Marzewski, et al., 1982; Moufarrij,
et al., 1984; Chimowitz, et al., 1995; Thijs, et al.,
2000; Qureshi, et al., 2003). Of the six
publications, two studies (Marzewski, et al.,
1982; Moufarrij, et al., 1984) insufficiently
detailed; focus is placed on the remaining four
publications in addition to the article describing
the WASID trial results (Chimowitz, et al.
2005). (Relevant features of these studies, along
with pertinent effect estimates, are summarized
in Table 1.)
Study 1: Millikan, et al. (1954)
examined Mayo Clinic patients with either
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Table 1: Data Used in Study Analyses
Study
Number &
Author(s)

Year

Endpoint

Warfarin:
#events/
#observations

Aspirin:
#events/
#observations

Aspirin/Warfarin
ratio (95% CI)

Log(ratio)
and (sd)

Caveat*

(1)
Millikan,
et al.

1954

Death

3 / 21 patients

10 / 23 patients

4.62 (2.18, 9.79)

1.53 (0.75)

A

(2)
Chimowitz,
et al.

1995

Stroke, MI,
sudden death

26 / 143
patient-year

14 / 166 patientyear

2.17 (1.16, 4.35)

0.63 (0.33)

B

(3)
Thijs and
Albers

2000

Cerebral
ischemic
events

Not given

Not given

4.9 (1.7, 13.9)

0.77 (0.33)

C

(4)
Qureshi,
et al.

2003

Stroke or
death

10 / 619
patient-month

8 / 787 patientmonth

0.63 (0.25, 1.59)

-0.46 (0.47)

D

2005

Ischemic
stroke, brain
hemorrhage,
vascular
death

62 / 504.4
patient-year

63 / 541.7
patient-year

1.04 (0.73, 1.48)

0.06 (0.18)

(5)
Chimowitz,
et al.

Caveats:
A: The treatment received by patients not receiving warfarin is unclear as are the inclusion criteria
B: Retrospective study possibly subject to selection bias
C: HRR is adjusted for age, presence of anterior circulation disease, Caucasian race, hyperlipidemia
D: Unpublished result from data supporting paper; Qureshi & Suri, personal communication, December 22, 2005

HR of 55.6 (95% CI, 9.1, 333), comparing
stroke free survival for patients receiving either
warfarin or aspirin to patients receiving neither
after adjustment for sex, race, hypertension,
diabetes
mellitus,
cigarette
smoking,
hyperlipidemia, and lesion location. Additional
data provided by the authors (Table 2) allowed
calculation of the aspirin to warfarin HR as 0.63
(95% CI, 0.25, 1.59).
Study 5: Chimowitz, et al. (2005) was
the only RCT comparing warfarin to aspirin in
patients with this disease. 569 patients were
followed for an average of 1.8 years. The aspirin
to warfarin HR is 1.04 (95% CI, 0.74, 1.49).

Table 2: Endpoints (Stroke or Death) in
Qureshi, et al. (2003)*
Warfarin
Aspirin
(n=46)

(n =40)

Number of Patients

46

40

Stroke or Death

10

8

Person-Months to
619
787
Endpoint
*Qureshi & Suri, personal communication,
December 22, 2005
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results may also be viewed as events per personyears of observation per group. In this case
Poisson hierarchical models can be used as
follows:

Methodology
Bayesian Learning
Because the results of these studies were
accumulated over 50 years, a Bayesian learning
approach was first used in which the posterior
distribution derived from the analysis of the
oldest result was used as the prior distribution in
order to derive the posterior distribution with the
next study. The goal was to estimate the
posterior distribution of θ, the unknown mean of
the distribution of log(RRR) from its prior and
the preceding study results with the posterior
distribution derived from study i-1 serving as the
prior distribution for study i for i = 2,…5. This is
expressed as follows:
Let Yi = log(RRRi).

For group j in study i let the number of
events, Eij ~ Poiss (nij × exp(φxj + εij)),
where xj is an indicator variable denoting
aspirin group membership, εij ~ N(0, σ2ε)
and φ ~ N(0, σ2φ). Here nij, the number of
person years at risk, is an offset term and φ
is the population value for log(RRR).
For each of these analyses a posterior mean was
generated with 95% Bayes interval and posterior
median with 50% Bayes interval or inter-quartile
range.
For each analysis three different
baseline priors were used as follows:
1) θ ~ N(0, 10) (a weakly non-informative
prior; warfarin has no effect);
2) θ ~ N(0, 0.5) (a skeptical prior; warfarin
has no effect);
3) θ ~ N(0.5, 10) (an enthusiastic prior;
warfarin reduces risk by 40%).
Additional sensitivity analyses included only
studies 2, 4 and 5.
As the Bayesian learning analysis
proceeded, graphs of the posterior, likelihood
and prior functions were inspected at each step.
Thus, the relative influence that the likelihood
and prior exerted in determination of the
resulting posterior was able to be determined.

Assuming that Yi is a realization from a random
distribution depending on θ, the Bayes theorem
gives
f(θ|Y1) ∝ f(Y1| θ) × f(θ),
(1)
f(θ|Y2) ∝ f(Y2| θ) × f(θ|Y1).

(2)

In general f(θ|Yi) ∝ f(Yi| θ) × f(θ|Yi-1), where
f(θ) is the baseline prior distribution for θ and i >
1, assuming that log(RRR) is normally
distributed, using the normal distribution for the
likelihood and its conjugate, the normal
distribution, as the prior for θ.
Hierarchical Random Effects Models
A simultaneous analysis in a
hierarchical random effects model was also
considered, specifically each has an estimate Yi
of a treatment effect θi, such that:
Yi ~ f(yi | θi).

Numerical Methods
In addition to the distributions for the
parameters of interest, non-informative prior
distributions were placed on any nuisance
parameters (e.g., σ2ε in the hierarchical Poisson
model) then integrated over these parameters in
the posterior distribution. For estimation, Gibbs
sampling (Casella & George, 1992) was used as
performed in the WinBUGS software
(Spiegelhalter, Thomas, Best, Gilks & Lunn,
2003). Convergence was monitored using the
scale reduction factor (SRF) (Gelman, et al.,
2004). For each model analyzed, 3 chains were
run with 1,000 iterations each (discarding the
first 500 in each chain). For analyses which
resulted in SRF > 1.1 the number of iterations
was increased in each chain by a factor of 10 the

(3)

These treatment effects are treated as
realizations of random variables from the same
population, that is,
θi ~ f(θi | θµ),

(4)

with θµ having its own prior distribution f(θµ).
Because all of the studies present an
estimate of risk which, after transformation, has
a normal distribution, a normal distribution was
used for functional forms of likelihood and prior
distribution functions. For some studies the
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from the non-informative prior tend to be much
higher than corresponding point estimates
stemming from skeptical and enthusiastic priors
at each point. This disparity is due to the
difference in variance between the noninformative prior versus skeptical and
enthusiastic priors.
A hypothetical future study of warfarin
and aspirin would incorporate the results of
study 5. With this addition, note that interval
estimates stemming from initial non-informative
and skeptical priors now include 1. Indeed, the
Bayes interval from the initial skeptical prior
now excludes 1.5 to the right. The Bayes
interval stemming from the enthusiastic prior
excludes 1 but covers 1.5 (the alternative
hypothesis for WASID) and 2.
Sensitivity analyses including only
studies 2, 4 and 5 result in posterior point and
interval estimates that are not much different
after adding study 4 into the analysis, especially
with the skeptical and enthusiastic priors (Table
4). The results after introduction of only study 2
are like the results after inclusion of both studies
1 and 2, suggesting that the optimistic estimates
from study 1 do not contribute substantially to
the overall conclusion. Additional sensitivity
analysis including study 4 produced posterior
point and interval estimates that were virtually
identical suggesting that study 4 does not have a
substantial impact on the analysis.

program run again until the SRF ≤ 1.1. Note that
such increases were only necessary for analysis
of the hierarchical random effects Poisson
models.
Results
Bayesian Learning Analyses
The results of the sequential Bayesian
learning analysis with log(RRR) as a normal
variate using studies 1-4 are shown in Table 3.
Note that the Bayesian results that were
available at the time that WASID began (studies
1 and 2) were mixed in their support for an
effect of warfarin as hypothesized for the
WASID clinical trial, i.e., RRR = .33 / .22 = 1.5,
versus the null hypothesis RRR = 1.
Specifically, although the 95% Bayes
intervals based on the initial informative prior or
the initial enthusiastic prior include 1.5 but
exclude 1, the interval based on the initial
skeptical prior includes both values. With the
subsequent addition of study 3’s results the
evidence favoring warfarin grew stronger. The
95% Bayes intervals stemming from both initial
skeptical and initial enthusiastic priors now
include 1.5 but exclude 1. Moreover the interval
stemming from the initial non-informative prior
excludes both 1 and 1.5 to the left. Addition of
study 4 has little effect on point and interval
estimates. Further point estimates stemming

Table 3: Posterior Point and Interval Estimates for θ = RRR from Bayesian Learning Analysis Using All Studies
Study
Added
1

2

3

4

5

Interval Type

Non-Informative Prior

Skeptical Prior

Enthusiastic Prior

Mean θ (95% Bayes interval)

4.48 (1.14, 17.64)

1.11 (0.75, 1.63)

1.82 (1.23, 2.69)

Median θ (50% Bayes interval)

4.48 (2.72, 7.39)

1.22 (1.0, 1.35)

1.82 (1.49, 2.23)

Mean θ (95% Bayes interval)

2.46 (1.36, 4.44)

1.35 (0.91, 1.99)

1.82 (1.23, 2.69)

Median θ (50% Bayes interval)

2.46 (2.01, 3.00)

1.35 (1.22, 1.49)

1.82 (1.65, 2.01)

Mean θ (95% Bayes interval)

3.00 (1.67, 5.42)

1.65 (1.12, 2.44)

2.01 (1.36, 2.97)

Median θ (50% Bayes interval)

3.00 (2.46, 3.67)

1.65 (1.49, 1.82)

2.01 (1.82, 2.46)

Mean θ (95% Bayes interval)

2.72 (1.65, 4.95)

1.65 (1.11, 2.46)

2.01 (1.35, 3.00)

Median θ (50% Bayes interval)

2.72 (2.23, 3.32)

1.65 (1.49, 1.82)

2.01 (1.82, 2.23)

Mean θ (95% Bayes interval)

1.35 (1.00, 2.01)

1.35 (1.00, 1.43)

1.49 (1.11, 2.01)

Median θ (50% Bayes interval)

1.49 (1.22, 1.65)

1.35 (1.22, 1.49)

1.49 (1.35, 1.65)
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The HR from a Poisson model that
compares events per person year between
thegroups was examined, with interest in the
ratio between the two Poisson parameters, which
are an estimate of RRR. Since not all studies
were sufficiently detailed in their report of rates,
these analyses are limited. Nevertheless the
extent of knowledge for 3 of the existing studies
and subsets was examined.
The results of these analyses are shown
in Table 6. The first analysis, using only study 2,
represents a simple Bayesian analysis using a
Poisson distribution. Note that the value of 1.5 is
included in the 95% Bayes interval estimates,
while the null value 1.0 is excluded by the
analysis using the non-informative and
enthusiastic priors. The other two analyses used
a hierarchical random effects Poisson model to
adjust for differences between studies. In these
analyses using studies 2 and 4 or using studies 2,
4, and 5, the 95% Bayes interval estimates
include both 1 and 1.5.

Simultaneous Analysis of RRR Using
Hierarchical Random Effects Models with the
Normal Distribution
The simultaneous analysis of these
studies was examined in the normal model for
log(RRR). Posterior point and interval estimates
for the analyses of various subsets of studies are
shown in Table 5. The results are very similar to
the results of the comparable Bayesian learning
analysis, although with wider intervals,
indicating different consequences of the ways
these methods address variability between
studies. Specifically the Bayesian learning
analysis provides for a posterior variance
estimate at each step, but this estimate can drift
between steps. In comparison, the simultaneous
nature of the hierarchical models requires
adjustment over all studies at once.
Simultaneous Analysis of RRR Using
Hierarchical Random Effects with the Poisson
Distribution

Table 4: Posterior Point and Interval Estimates for θ = RRR from Bayesian Learning Analysis Using
Restricted Set of Studies
Study
Added
2

4

5

Interval Type

Non-Informative
Prior

Skeptical Prior

Enthusiastic Prior

Mean θ (95% Bayes interval)

2.23 (1.23, 4.01)

1.35 (0.91, 1.99)

1.82 (1.23, 2.69)

Median θ (50% Bayes interval)

2.23 (1.82, 2.72)

1.35 (1.22, 1.65)

1.82 (1.65, 2.01)

Mean θ (95% Bayes interval)

2.01 (1.22, 3.67)

1.35 (0.90, 2.01)

1.82 (1.22, 2.72)

Median θ (50% Bayes interval)

2.23 (1.82, 2.46)

1.35 (1.22, 1.49)

1.82 (1.65, 2.01)

Mean θ (95% Bayes interval)

1.35 (0.90, 1.82)

1.22 (0.90, 1.65)

1.35 (1.11, 1.82)

Median θ (50% Bayes interval)

1.35 (1.11, 1.49)

1.22 (1.11, 1.35)

1.35 (1.22, 1.49)
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some
have Effects
not been
so
Table 5: Posterior Point and Interval estimates for θ = intracranial
RRR Using stenosis,
Hierarchical
Random
Model
quick
to
proclaim
with Normal Distribution
Studies
Included
1, 2, 3, 4
1, 2, 3,
4, 5
2, 4

2, 4, 5

Interval Type

Non-Informative
Prior

Skeptical Prior

Enthusiastic Prior

Mean θ (95% Bayes interval)

2.72 (0.27, 14.88)

1.11 (0.67, 1.82)

1.82 (1.22, 3.00)

Median θ (50% Bayes interval)

3.00 (2.01, 4.06)

1.11 (1.00, 1.35)

1.82 (1.65, 2.23)

Mean θ (95% Bayes interval)

2.01 (0.55, 6.69)

1.22 (0.74, 1.82)

1.82 (1.22, 2.72)

Median θ (50% Bayes interval)

2.01 (1.49, 2.72)

1.22 (1.00, 1.35)

1.82 (1.49, 2.01)

Mean θ (95% Bayes interval)

1.49 (0, 4.9 x 105)

1.00 (0.67, 1.65)

1.65 (1.00, 2.72)

Median θ (50% Bayes interval)

1.82 (0.27, 7.39)

1.00 (0.90, 1.22)

1.65 (1.35, 2.01)

Mean θ (95% Bayes interval)

1.22 (0.07, 20.1)

1.11 (0.67, 1.65)

1.49 (1.11, 2.46)

Median θ (50% Bayes interval)

1.35 (0.90, 2.01)

1.11 (1.00, 1.22)

1.49 (1.35, 1.82)

warfarin’s demise (Koroshetz, 2005). In this
presentation we explore application of Bayesian
methods to interpret the WASID results in light
of the overall accumulation of evidence
regarding the effect of warfarin and consider
what insights the Bayesian analyses might have
indicated along the way?
At the time of the WASID proposal
submission, the accumulated evidence taken
from the Bayesian learning perspective fit neatly
with the standard of equipoise necessary to
justify NIH funding. Specifically, those coming
to the debate with no or vague prior beliefs (i.e.,
the non-informative prior) as well as those
favoring warfarin (i.e., the enthusiast) could
justify RRR = 1.5 and exclude RRR = 1. On the
other hand, those coming to the problem
favoring no difference (i.e., the skeptic) could
justify both values for RRR. With the
hierarchical analyses the alignments of skeptics
and enthusiasts remain the same, while those
with vague beliefs now align with the skeptics.
In July 2003, when the study was
terminated for safety reasons, the results of the
Bayesian learning analyses all excluded RRR =
1 from interval estimates, regardless of prior
beliefs. When the analysis is restricted to studies
meeting perceived quality criteria, the initial
state of equipoise described above remained.

Conclusion
Reconciliation of the results of WASID with
previous reports of a strong effect of warfarin is
difficult. Many would advocate that the biases of
the prior observational studies should discount
those results in favor of the unbiased result of
the RCT. Certainly the use of randomization,
blinding, standardization of patient management
protocols, and central endpoint adjudication
ensure bias-free estimate of treatment effect
from the RCT. However, RCTs are not without
other sources of bias stemming from the
selection of participating physicians and clinics
as well as the enrollment of consenting patients.
Thus, a growing community of investigators
(Berry, et al., 2003; Brophy & Lawrence, 1995;
Diamond & Kaul, 2004) advocates the use of
Bayesian statistical methods to interpret results
of clinical trials as well as to synthesize
evidence from a set of studies about the effect of
treatment(s). Bayesian statistical methods have
recently gained notice in the arena of stroke
clinical trials (Berry, 2005; Donnan, et al., 2005;
Howard, et al., 2005; Krams, et al., 2005).
Although taken as a single trial the
WASID results would seem to extinguish the
utility of warfarin as a secondary prevention
strategy for patients with symptomatic
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The ability to generate interval estimates
and use differing priors deepens understanding
of the current evidence in light of previous
studies. These results point to the utility of
Bayesian analyses of prior studies as an
additional tool for monitoring clinical trials. The
concordance of frequentist and Bayesian
efficacy analyses would provide robust
confirmation of the appropriateness of a futility
analysis when decisions regarding the
continuation or stopping of a clinical trial are
made.

Moreover, the hierarchical analyses limited to
published results as of July 2003 would be no
different than before. However, the inclusion of
the rates from study 4, if they had been
published at that time, leads to hierarchical
model results that lend support for both
RRR=1.5 or RRR=1 regardless of prior belief.
The lack of strict correspondence between
conclusions from Bayesian learning with those
from Bayesian hierarchical random effects
models results from differences between
methods in incorporating between-study
variability. The studies do have differences in
design (sample size, endpoint definitions and
inclusion criteria) warranting allowances in the
modeling process. Although none of studies 1-4
were randomized clinical trials, hierarchical
models can be extended to adjust for different
classes (such as RCTs versus non-randomized
studies) when 2 or more studies of each class are
present. Unfortunately only one RCT was
available to include.
It is particularly interesting to note the
change in conclusions wrought by the
unpublished, negative result of Study 4. This
finding reinforces the importance of finding all
results, even negative ones, in compiling
evidence.
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1.65 (0.67, 4.48)

Median φ (50% Bayes interval)

0.41 (0.01, 22.20)

1.0 (0.74. 1.35)

1.65 (1.22, 2.23)

Mean φ (95% Bayes interval)

1.11 (0, 24300)

1.0 (0.41, 2.72)

1.65 (0.55, 4.48)

1.11 (0.03, 54.6)

1.0 (0.74, 1.35)

1.65 (1.11, 2.23)

Median φ (50% Bayes interval)
*Uses simple Poisson model for two groups
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